Company Overview
Snapshot
Founded in July 2021, 1E Therapeutics operates with 11–50 employees. The company has raised $120 million across one funding round. In December 2021, the company secured a significant seed round.
Business overview
1E Therapeutics is a drug-development company focused on creating RNA-targeting therapeutics. The company leverages a proprietary drug-design platform to develop compounds addressing a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology, 1E Therapeutics targets the pharmaceuticals market with its drug discovery and development efforts.
Strategic signal
In December 2021, 1E Therapeutics secured a $120 million Seed round, just five months after its founding. This substantial initial investment signals strong investor confidence in the company's proprietary RNA-targeting drug-design platform and its potential to address chronic life-threatening indications and emerging pathogens. For investors, this demonstrates significant early-stage validation and a rapid acceleration into the competitive drug development landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is 1E Therapeutics' core focus?
- 1E Therapeutics specializes in the development of novel RNA-targeting drugs, utilizing a proprietary drug-design platform to address various medical conditions.
- When was 1E Therapeutics founded?
- 1E Therapeutics was founded in July 2021.
- How much capital has 1E Therapeutics raised?
- 1E Therapeutics has raised a total of $120 million across one funding round.
- Which investor participated in 1E Therapeutics' seed round?
- In December 2021, Marius Nacht participated in 1E Therapeutics' seed funding round.
- What types of diseases does 1E Therapeutics aim to address?
- 1E Therapeutics is developing lead compounds to address a wide array of indications including oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.